About this Journal Submit a Manuscript Table of Contents
Gastroenterology Research and Practice
Volume 2012 (2012), Article ID 757926, 9 pages
http://dx.doi.org/10.1155/2012/757926
Review Article

Helicobacter  pylori Eradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved Efficacy

1Department of Gastroenterology, Athens Medical Center of P. Phaliron, P. Phaliron, 17562 Athens, Greece
2Department of Internal Medicine, General Hospital of Rhodes, 85100 Rhodes, Greece

Received 3 March 2012; Accepted 8 May 2012

Academic Editor: Ping-I Hsu

Copyright © 2012 Sotirios D. Georgopoulos et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Moayyedi and R. H. Hunt, “Helicobacter pylori public health implications,” Helicobacter, vol. 9, supplement 1, pp. 67–72, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Suerbaum and P. Michetti, “Helicobacter pylori infection,” The New England Journal of Medicine, vol. 347, no. 15, pp. 1175–1186, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. L. Fuccio, R. M. Zagari, L. H. Eusebi et al., “Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer?” Annals of Internal Medicine, vol. 151, no. 2, pp. 121–128, 2009. View at Scopus
  4. K. Fukase, M. Kato, S. Kikuchi et al., “Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial,” The Lancet, vol. 372, no. 9636, pp. 392–397, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. P. Malfertheiner, F. K. Chan, and K. E. McColl, “Peptic ulcer disease,” The Lancet, vol. 374, no. 9699, pp. 1449–1461, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Stathis, F. Bertoni, and E. Zucca, “Treatment of gastric marginal zone lymphoma of MALT type,” Expert Opinion on Pharmacotherapy, vol. 11, no. 13, pp. 2141–2152, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. D. Y. Graham, “Antibiotic resistance in Helicobacter pylori: implications for therapy,” Gastroenterology, vol. 115, no. 5, pp. 1272–1277, 1998. View at Publisher · View at Google Scholar · View at Scopus
  8. F. Mégraud, “H pylori antibiotic resistance: prevalence, importance, and advances in testing,” Gut, vol. 53, no. 9, pp. 1374–1384, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. F. Megraud, “Helicobacter pylori and antibiotic resistance,” Gut, vol. 56, no. 11, p. 1502, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. N. Broutet, S. Tchamgoué, E. Pereira, H. Lamouliatte, R. Salamon, and F. Mégraud, “Risk factors for failure of Helicobacter pylori therapy—results of an individual data analysis of 2751 patients,” Alimentary Pharmacology & Therapeutics, vol. 17, no. 1, pp. 99–109, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. S. D. Georgopoulos, S. D. Ladas, S. Karatapanis et al., “Factors that may affect treatment outcome of triple Helicobacter pylori eradication therapy with omeprazole, amoxicillin, and clarithromycin,” Digestive Diseases and Sciences, vol. 45, no. 1, pp. 63–67, 2000. View at Publisher · View at Google Scholar · View at Scopus
  12. “Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group,” Gut, vol. 41, no. 1, pp. 8–13, 1997. View at Scopus
  13. T. Lind, S. V. van Zanten, P. Unge et al., “Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I study,” Helicobacter, vol. 1, no. 3, pp. 138–144, 1996. View at Scopus
  14. V. De Francesco, M. Margiotta, A. Zullo et al., “Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15 year period in Italy,” Journal of Antimicrobial Chemotherapy, vol. 59, no. 4, pp. 783–785, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. J. P. Gisbert, R. Pajares, and J. M. Pajares, “Evolution of Helicobacter pylori therapy from a meta-analytical perspective,” Helicobacter, vol. 12, supplement 2, pp. 50–58, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. V. De Francesco, F. Giorgio, C. Hassan et al., “Worldwide H. pylori antibiotic resistance: a systematic review,” Journal of Gastrointestinal and Liver Diseases, vol. 19, no. 4, pp. 409–414, 2010. View at Scopus
  17. L. A. Fischbach, K. J. Goodman, M. Feldman, and C. Aragaki, “Sources of variation of Helicobacter pylori treatment success in adults worldwide: a meta-analysis,” International Journal of Epidemiology, vol. 31, no. 1, pp. 128–139, 2002. View at Scopus
  18. M. J. Janssen, A. H. Van Oijen, A. L. Verbeek, J. B. Jansen, and W. A. De Boer, “A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole,” Alimentary Pharmacology & Therapeutics, vol. 15, no. 5, pp. 613–624, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. R. J. Laheij, L. G. Rossum, J. B. Jansen, H. Straatman, and A. L. Verbeek, “Evaluation of treatment regimens to cure Helicobacter pylori infection—a meta-analysis,” Alimentary Pharmacology & Therapeutics, vol. 13, no. 7, pp. 857–864, 1999. View at Publisher · View at Google Scholar · View at Scopus
  20. P. Malfertheiner, F. Mégraud, C. O'Morain et al., “Current concepts in the management of Helicobacter pylori infection—the Maastricht 2-2000 Consensus Report,” Alimentary Pharmacology & Therapeutics, vol. 16, no. 2, pp. 167–180, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. P. H. Katelaris, G. M. Forbes, N. J. Talley, and B. Crotty, “A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: the QUADRATE study,” Gastroenterology, vol. 123, no. 6, pp. 1763–1769, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. X. Calvet, J. Ducons, J. Guardiola et al., “One-week triple vs. quadruple therapy for Helicobacter pylori infection—a randomized trial,” Alimentary Pharmacology & Therapeutics, vol. 16, no. 7, pp. 1261–1267, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Luther, P. D. Higgins, P. S. Schoenfeld, P. Moayyedi, N. Vakil, and W. D. Chey, “Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: systematic review and meta-analysis of efficacy and tolerability,” American Journal of Gastroenterology, vol. 105, no. 1, pp. 65–73, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. D. Y. Graham and M. P. Dore, “Helicobacter pylori therapy demystified,” Helicobacter, vol. 16, no. 5, pp. 343–345, 2011.
  25. W. D. Chey and B. C. Wong, “American College of Gastroenterology guideline on the management of Helicobacter pylori infection,” American Journal of Gastroenterology, vol. 102, no. 8, pp. 1808–1825, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Caselli, A. Zullo, G. Maconi et al., “‘Cervia II Working Group Report 2006’: guidelines on diagnosis and treatment of Helicobacter pylori infection in Italy,” Digestive and Liver Disease, vol. 39, no. 8, pp. 782–789, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. G. Maconi, C. Tosetti, G. Miroglio et al., “Management of Helicobacter pylori-related gastrointestinal diseases by general practitioners in Italy,” Alimentary Pharmacology & Therapeutics, vol. 13, no. 11, pp. 1499–1504, 1999. View at Publisher · View at Google Scholar · View at Scopus
  28. S. D. Georgopoulos, S. D. Ladas, S. Karatapanis et al., “Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies,” Alimentary Pharmacology & Therapeutics, vol. 16, no. 3, pp. 569–575, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. G. J. Mantzaris, K. Petraki, E. Archavlis et al., “Omeprazole triple therapy versus omeprazole quadruple therapy for healing duodenal ulcer and eradication of Helicobacter pylori infection: 24-month follow-up study,” European Journal of Gastroenterology and Hepatology, vol. 14, no. 11, pp. 1237–1243, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Karatapanis, S. D. Georgopoulos, V. Papastergiou, et al., “7, 10 and 14-days rabeprazole-based standard triple therapies for H. pylori eradication: are they still effective? A randomized trial,” Acta Gastroenterol Belg, vol. 74, no. 3, pp. 407–412, 2011.
  31. T. Rokkas, P. Sechopoulos, I. Robotis, G. Margantinis, and D. Pistiolas, “Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen,” American Journal of Gastroenterology, vol. 104, no. 1, pp. 21–25, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. L. Boyanova, A. Mentis, M. Gubina et al., “The status of antimicrobial resistance of Helicobacter pylori in Eastern Europe,” Clinical Microbiology and Infection, vol. 8, no. 7, pp. 388–396, 2002. View at Publisher · View at Google Scholar · View at Scopus
  33. Y. Glupczynski, F. Mégraud, M. Lopez-Brea, and L. P. Andersen, “European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori,” European Journal of Clinical Microbiology and Infectious Diseases, vol. 20, no. 11, pp. 820–823, 2001. View at Publisher · View at Google Scholar · View at Scopus
  34. A. F. Mentis, E. Roma, A. Pangalis, and E. Katsiyiannakis, “Susceptibilities of Helicobacter pylori strains isolated from children with gastritis to selected antibiotics,” Journal of Antimicrobial Chemotherapy, vol. 44, no. 5, pp. 720–722, 1999. View at Publisher · View at Google Scholar · View at Scopus
  35. J. P. Gisbert, J. L. Gisbert, S. Marcos, I. Jimenez-Alonso, R. Moreno-Otero, and J. M. Pajares, “Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients,” Alimentary Pharmacology & Therapeutics, vol. 27, no. 4, pp. 346–354, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. K. Seppälä, T. U. Kosunen, L. Veijola et al., “Cure of Helicobacter pylori infection in all compliant patients: report on 644 subjects,” Scandinavian Journal of Gastroenterology, vol. 43, no. 9, pp. 1149–1150, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. L. Fuccio, R. M. Zagari, and F. Bazzoli, “What is the best salvage therapy for patients with Helicobacter pylori infection?” Nature Clinical Practice Gastroenterology and Hepatology, vol. 5, no. 11, pp. 608–609, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Q. Huang and R. H. Hunt, “Treatment after failure: the problem of ‘non-responders’,” Gut, vol. 45, supplement 1, pp. I40–I44, 1999. View at Scopus
  39. S. K. Chuah, F. W. Tsay, P. I. Hsu, and D. C. Wu, “A new look at anti-Helicobacter pylori therapy,” World Journal of Gastroenterology, vol. 17, no. 35, pp. 3971–3975, 2011.
  40. D. Y. Graham, H. Lu, and Y. Yamaoka, “A report card to grade Helicobacter pylori therapy,” Helicobacter, vol. 12, no. 4, pp. 275–278, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. D. Y. Graham, “Efficient identification and evaluation of effective Helicobacter pylori therapies,” Clinical Gastroenterology and Hepatology, vol. 7, no. 2, pp. 145–148, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. D. Y. Graham and L. Fischbach, “Helicobacter pylori treatment in the era of increasing antibiotic resistance,” Gut, vol. 59, no. 8, pp. 1143–1153, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. J. P. Gisbert, X. Calvet, A. O'Connor, F. Mégraud, and C. A. O'Morain, “Sequential therapy for Helicobacter pylori eradication: a critical review,” Journal of Clinical Gastroenterology, vol. 44, no. 5, pp. 313–325, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. P. Moayyedi, “Sequential regimens for Helicobacter pylori eradication,” The Lancet, vol. 370, no. 9592, pp. 1010–1012, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. N. S. Jafri, C. A. Hornung, and C. W. Howden, “Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment,” Annals of Internal Medicine, vol. 148, no. 12, pp. 923–931, 2008. View at Scopus
  46. J. L. Tong, Z. H. Ran, J. Shen, and S. D. Xiao, “Sequential therapy vs. standard triple therapies for Helicobacter pylori infection: a meta-analysis,” Journal of Clinical Pharmacy and Therapeutics, vol. 34, no. 1, pp. 41–53, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. L. Gatta, N. Vakil, G. Leandro, F. Di Mario, and D. Vaira, “Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children,” American Journal of Gastroenterology, vol. 104, no. 12, pp. 3069–3079, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Zullo, V. De Francesco, C. Hassan, S. Morini, and D. Vaira, “The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis,” Gut, vol. 56, no. 10, pp. 1353–1357, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. D. Vaira, A. Zullo, N. Vakil et al., “Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial,” Annals of Internal Medicine, vol. 146, no. 8, pp. 556–563, 2007. View at Scopus
  50. D. C. Wu, P. I. Hsu, J. Y. Wu, et al., “Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection,” Clinical Gastroenterology and Hepatology, vol. 8, no. 1, pp. 36.e1–41.e1, 2010.
  51. I. T. Paulsen, M. H. Brown, and R. A. Skurray, “Proton-dependent multidrug efflux systems,” Microbiological Reviews, vol. 60, no. 4, pp. 575–608, 1996. View at Scopus
  52. M. A. Webber and L. J. Piddock, “The importance of efflux pumps in bacterial antibiotic resistance,” Journal of Antimicrobial Chemotherapy, vol. 51, no. 1, pp. 9–11, 2003. View at Publisher · View at Google Scholar · View at Scopus
  53. M. C. Roberts, “Resistance to macrolide, lincosamide, streptogramin, ketolide, and oxazolidinone antibiotics,” Molecular Biotechnology, vol. 28, no. 1, pp. 47–62, 2004. View at Publisher · View at Google Scholar · View at Scopus
  54. J. Molina-Infante, C. Pazos-Pacheco, and B. Perez-Gallardo, “Efficacy of nonbismuth quadruple “concomitant” therapy for H. pylori infection in a setting with high clarithromycin resistance,” Helicobacter, vol. 138, article 880, supplement 1, 2011.
  55. J. Molina-Infante, B. Perez-Gallardo, M. Fernandez-Bermejo et al., “Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication,” Alimentary Pharmacology & Therapeutics, vol. 31, no. 10, pp. 1077–1084, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. W. A. de Boer, E. J. Kuipers, and J. G. Kusters, “Sequential therapy; a new treatment for Helicobacter pylori infection: but is it ready for general use?” Digestive and Liver Disease, vol. 36, no. 5, pp. 311–314, 2004. View at Publisher · View at Google Scholar · View at Scopus
  57. J. Sánchez-Delgado, X. Calvet, L. Bujanda, J. P. Gisbert, L. Titó, and M. Castro, “Ten-day sequential treatment for Helicobacter pylori eradication in clinical practice,” American Journal of Gastroenterology, vol. 103, no. 9, pp. 2220–2223, 2008. View at Publisher · View at Google Scholar · View at Scopus
  58. C. A. O'Morain and J. P. O'Connor, “Is sequential therapy superior to standard triple therapy for the treatment of Helicobacter pylori infection?” Nature Clinical Practice Gastroenterology and Hepatology, vol. 6, no. 1, pp. 8–9, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. P. Moayyedi and P. Malfertheiner, “Editorial: sequential therapy for eradication of Helicobacter pylori: a new guiding light or a false dawn?” American Journal of Gastroenterology, vol. 104, no. 12, pp. 3081–3083, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. J. Luther and W. D. Chey, “Sequential therapy for Helicobacter pylori: a two for one deal that's worth the extra effort?” Gastroenterology, vol. 136, no. 2, pp. 720–722, 2009. View at Publisher · View at Google Scholar · View at Scopus
  61. W. H. Choi, D. I. Park, S. J. Oh et al., “Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea,” The Korean Journal of Gastroenterology, vol. 51, no. 5, pp. 280–284, 2008. View at Scopus
  62. X. Z. Gao, X. L. Qiao, W. C. Song, X. F. Wang, and F. Liu, “Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication,” World Journal of Gastroenterology, vol. 16, no. 34, pp. 4357–4362, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. E. R. Greenberg, G. L. Anderson, D. R. Morgan et al., “14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial,” The Lancet, vol. 378, no. 9790, pp. 507–514, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. D. Y. Graham and E. Rimbara, “Understanding and appreciating sequential therapy for Helicobacter pylori eradication,” Journal of Clinical Gastroenterology, vol. 45, no. 4, pp. 309–313, 2011. View at Publisher · View at Google Scholar · View at Scopus
  65. H. G. Park, M. K. Jung, J. T. Jung, et al., “Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naive patients,” Alimentary Pharmacology & Therapeutics, vol. 35, no. 1, pp. 56–65, 2012.
  66. A. Merali and G. I. Leontiadis, “Sequential therapy—more studies are still required,” Alimentary Pharmacology & Therapeutics, vol. 35, no. 1, pp. 194–195, 2012.
  67. J. P. Gisbert and X. Calvet, “Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori,” Alimentary Pharmacology & Therapeutics, vol. 34, no. 6, pp. 604–617, 2011. View at Publisher · View at Google Scholar · View at Scopus
  68. H. Fakheri, T. Taghvaei, V. Hosseini, and Z. Bari, “A comparison between sequential therapy and a modified bismuth-based quadruple therapy for Helicobacter pylori eradication in Iran: a randomized clinical trial,” Helicobacter, vol. 17, no. 1, pp. 43–48, 2012.
  69. D. Y. Graham and A. Shiotani, “New concepts of resistance in the treatment of Helicobacter pylori infections,” Nature Clinical Practice Gastroenterology and Hepatology, vol. 5, no. 6, pp. 321–331, 2008. View at Publisher · View at Google Scholar · View at Scopus
  70. G. Treiber, J. Wittig, S. Ammon, S. Walker, L. J. van Doorn, and U. Klotz, “Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study),” Archives of Internal Medicine, vol. 162, no. 2, pp. 153–160, 2002. View at Scopus
  71. A. S. Essa, J. R. Kramer, D. Y. Graham, and G. Treiber, “Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing “concomitant therapy” versus triple therapy for Helicobacter pylori eradication,” Helicobacter, vol. 14, no. 2, pp. 109–118, 2009. View at Publisher · View at Google Scholar · View at Scopus
  72. L. A. Fischbach, L. E. Bravo, G. R. Zarama et al., “A randomized clinical trial to determine the efficacy of regimens containing clarithromycin, metronidazole, and amoxicillin among histologic subgroups for Helicobacter pylori eradication in a developing country,” Helicobacter, vol. 14, no. 2, pp. 100–108, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. P. I. Hsu, D. C. Wu, J. Y. Wu, and D. Y. Graham, “Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicilin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days,” Helicobacter, vol. 16, no. 2, pp. 146–152, 2011. View at Publisher · View at Google Scholar · View at Scopus
  74. S. Georgopoulos, V. Papastergiou, E. Xirouchakis, et al., “Evaluation of a four-drug, three-antibiotic, nonbismuth-containing “concomitant” therapy as first-line Helicobacter pylori eradication regimen in Greece,” Helicobacter, vol. 16, no. 2, pp. 139–145, 2011.
  75. S. D. Georgopoulos, E. Xirouchakis, and F. Laoudi, “Clinical evaluation of a 10-day regimenwith esomeprazole, metronidazole, amoxycilline and clarithromycin for the eradication of Helicobacter pylori (E-MACH study),” Helicobacter, vol. 16, article A136, supplement 1, 2011.
  76. J. M. Liou, J. T. Lin, C. Y. Chang et al., “Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design,” Gut, vol. 59, no. 5, pp. 572–578, 2010. View at Publisher · View at Google Scholar · View at Scopus
  77. P. Malfertheiner, F. Megraud, C. O'Morain et al., “Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report,” Gut, vol. 56, no. 6, pp. 772–781, 2007. View at Publisher · View at Google Scholar · View at Scopus
  78. L. A. Fischbach, S. van Zanten, and J. Dickason, “Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies,” Alimentary Pharmacology & Therapeutics, vol. 20, no. 10, pp. 1071–1082, 2004. View at Publisher · View at Google Scholar · View at Scopus
  79. L. Fischbach and E. L. Evans, “Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori,” Alimentary Pharmacology & Therapeutics, vol. 26, no. 3, pp. 343–357, 2007. View at Publisher · View at Google Scholar · View at Scopus
  80. S. Michopoulos, P. Tsibouris, H. Bouzakis et al., “Randomized study comparing omeprazole with ranitidine as anti-secretory agents combined in quadruple second-Iine Helicobacter pylori eradication regimens,” Alimentary Pharmacology & Therapeutics, vol. 14, no. 6, pp. 737–744, 2000. View at Publisher · View at Google Scholar · View at Scopus
  81. F. Perri, V. Festa, A. Merla, M. Quitadamo, R. Clemente, and A. Andriulli, “Amoxicillin/tetracycline combinations are inadequate as alternative therapies for Helicobacter pylori infection,” Helicobacter, vol. 7, no. 2, pp. 99–104, 2002. View at Publisher · View at Google Scholar · View at Scopus
  82. N. Garcia, X. Calvet, E. Gene, R. Campo, and E. Brullet, “Limited usefulness of a seven-day twice-a-day quadruple therapy,” European Journal of Gastroenterology and Hepatology, vol. 12, no. 12, pp. 1315–1318, 2000. View at Scopus
  83. W. A. de Boer, R. J. van Etten, P. M. Schneeberger, and G. N. Tytgat, “A single drug for Helicobacter pylori infection: first results with a new bismuth triple monocapsule,” American Journal of Gastroenterology, vol. 95, no. 3, pp. 641–645, 2000. View at Publisher · View at Google Scholar · View at Scopus
  84. W. A. de Boer, “A novel therapeutic approach for Helicobacter pylori infection: the bismuth-based triple therapy monocapsule,” Expert Opinion on Investigational Drugs, vol. 10, no. 8, pp. 1559–1566, 2001. View at Publisher · View at Google Scholar · View at Scopus
  85. L. Laine, R. Hunt, H. EI-Zimaity, B. Nguyen, M. Osato, and J. Spénard, “Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial,” American Journal of Gastroenterology, vol. 98, no. 3, pp. 562–567, 2003. View at Publisher · View at Google Scholar · View at Scopus
  86. C. O'Morain, T. Borody, A. Farley et al., “Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study,” Alimentary Pharmacology & Therapeutics, vol. 17, no. 3, pp. 415–420, 2003. View at Publisher · View at Google Scholar · View at Scopus
  87. A. Saleem, A. Qasim, H. J. O'Connor, and C. A. O'Morain, “Pylera for the eradication of Helicobacter pylori infection,” Expert Review of Anti-Infective Therapy, vol. 7, no. 7, pp. 793–799, 2009. View at Publisher · View at Google Scholar · View at Scopus
  88. P. Malfertheiner, F. Bazzoli, J. C. Delchier et al., “Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial,” The Lancet, vol. 377, no. 9769, pp. 905–913, 2011. View at Publisher · View at Google Scholar · View at Scopus
  89. M. Romano, A. Cuomo, A. G. Gravina et al., “Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial,” Gut, vol. 59, no. 11, pp. 1465–1470, 2010. View at Publisher · View at Google Scholar · View at Scopus
  90. M. Berning, S. Krasz, and S. Miehlke, “Should quinolones come first in Helicobacter pylori therapy?” Therapeutic Advances in Gastroenterology, vol. 4, no. 2, pp. 103–114, 2011. View at Publisher · View at Google Scholar · View at Scopus
  91. F. Perna, A. Zullo, C. Ricci, C. Hassan, S. Morini, and D. Vaira, “Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance,” Digestive and Liver Disease, vol. 39, no. 11, pp. 1001–1005, 2007. View at Publisher · View at Google Scholar · View at Scopus
  92. P. Bogaerts, C. Berhin, H. Nizet, and Y. Glupczynski, “Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pylori strains from patients living in Belgium,” Helicobacter, vol. 11, no. 5, pp. 441–445, 2006. View at Publisher · View at Google Scholar · View at Scopus
  93. J. J. Carothers, M. G. Bruce, T. W. Hennessy et al., “The relationship between previous fluoroquinolone use and levofloxacin resistance in Helicobacter pylori infection,” Clinical Infectious Diseases, vol. 44, no. 2, pp. e5–e8, 2007. View at Publisher · View at Google Scholar · View at Scopus
  94. P. D. van der Linden, M. C. Sturkenboom, R. M. Herings, H. G. Leufkens, and B. H. Stricker, “Fluoroquinolones and risk of achilles tendon disorders: case-control study,” British Medical Journal, vol. 324, no. 7349, pp. 1306–1307, 2002. View at Scopus
  95. K. F. Croom and K. L. Goa, “Levofloxacin: a review of its use in the treatment of bacterial infections in the United States,” Drugs, vol. 63, no. 24, pp. 2769–2802, 2003. View at Publisher · View at Google Scholar · View at Scopus
  96. C. Bilardi, P. Dulbecco, P. Zentilin et al., “A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: a controlled trial,” Clinical Gastroenterology and Hepatology, vol. 2, no. 11, pp. 997–1002, 2004. View at Publisher · View at Google Scholar · View at Scopus
  97. R. J. Saad, P. Schoenfeld, H. M. Kim, and W. D. Chey, “Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis,” American Journal of Gastroenterology, vol. 101, no. 3, pp. 488–496, 2006. View at Publisher · View at Google Scholar · View at Scopus
  98. J. P. Gisbert, F. Bermejo, M. Castro-Fernández et al., “Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients,” American Journal of Gastroenterology, vol. 103, no. 1, pp. 71–76, 2008. View at Publisher · View at Google Scholar · View at Scopus
  99. J. P. Gisbert, “Second-line rescue therapy of Helicobacter pylori infection,” Therapeutic Advances in Gastroenterology, vol. 2, no. 6, pp. 331–356, 2009. View at Publisher · View at Google Scholar · View at Scopus
  100. J. P. Gisbert, J. L. Gisbert, S. Marcos, R. Moreno-Otero, and J. M. Pajares, “Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures,” Alimentary Pharmacology & Therapeutics, vol. 24, no. 10, pp. 1469–1474, 2006. View at Publisher · View at Google Scholar · View at Scopus
  101. T. Nishizawa, H. Suzuki, and T. Hibi, “Quinolone-based third-line therapy for Helicobacter pylori eradication,” Journal of Clinical Biochemistry and Nutrition, vol. 44, no. 2, pp. 119–124, 2009. View at Publisher · View at Google Scholar · View at Scopus
  102. S. Karatapanis, L. Skorda, S. D. Georgopoulos et al., “Levofloxacin-based triple therapy versus bismuth-based quadruple therapy as a second line treatment for the eradication of H. pylori infection,” Annals of Gastroenterology, vol. 22, no. 4, pp. 263–267, 2009. View at Scopus
  103. C. Krystallis, D. Kamberoglou, D. Pistiolas et al., “A new second-line sequential regimen for Helicobacter pylori eradication based on levofloxacin: a pilot study,” Digestive Diseases and Sciences, vol. 55, no. 12, pp. 3630–3631, 2010. View at Publisher · View at Google Scholar · View at Scopus
  104. S. Pontone, M. Standoli, R. Angelini, and P. Pontone, “Efficacy of H. pylori eradication with a sequential regimen followed by rescue therapy in clinical practice,” Digestive and Liver Disease, vol. 42, no. 8, pp. 541–543, 2010. View at Publisher · View at Google Scholar · View at Scopus
  105. D. Y. Graham, M. S. Osato, J. Hoffman et al., “Metronidazole containing quadruple therapy for infection with metronidazole resistant Helicobacter pylori: a prospective study,” Alimentary Pharmacology & Therapeutics, vol. 14, no. 6, pp. 745–750, 2000. View at Publisher · View at Google Scholar · View at Scopus
  106. B. H. Lee, N. Kim, T. J. Hwang et al., “Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea,” Helicobacter, vol. 15, no. 1, pp. 38–45, 2010. View at Publisher · View at Google Scholar · View at Scopus
  107. Q. Sun, X. Liang, Q. Zheng et al., “High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication,” Helicobacter, vol. 15, no. 3, pp. 233–238, 2010. View at Publisher · View at Google Scholar · View at Scopus
  108. D. Y. Graham, S. U. Javed, S. Keihanian, S. Abudayyeh, and A. R. Opekun, “Dual proton pump inhibitor plus amoxicillin as an empiric anti-H. pylori therapy: studies from the United States,” Journal of Gastroenterology, vol. 45, no. 8, pp. 816–820, 2010. View at Scopus
  109. E. Rimbara, L. A. Fischbach, and D. Y. Graham, “Optimal therapy for Helicobacter pylori infections,” Nature Reviews Gastroenterology and Hepatology, vol. 8, no. 2, pp. 79–88, 2011. View at Publisher · View at Google Scholar · View at Scopus
  110. J. P. Gisbert and X. Calvet, “Review article: rifabutin in the treatment of refractory Helicobacter pylori infection,” Alimentary Pharmacology & Therapeutics, vol. 35, no. 2, pp. 209–221, 2012.
  111. G. Treiber, S. Ammon, P. Malfertheiner, and U. Klotz, “Impact of furazolidone-based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures,” Helicobacter, vol. 7, no. 4, pp. 225–231, 2002. View at Publisher · View at Google Scholar · View at Scopus
  112. P. Malfertheiner, F. Megraud, C. A. O'Morain, et al., “Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report,” Gut, vol. 61, no. 5, pp. 646–664, 2012.